Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in TP53, PTEN and RB1 on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer.

CONCLUSIONS: This study identified a unique molecular signature consisting of combined aberrations in TP53, PTEN and RB1 that is associated with poorer overall survival, as well as increasing prevalence of ETS gene fusions and differential gene expression patterns favoring aggressive disease and tumor progression. Identification of this subset of patients could inform prognostic decisions and provide a rationale for more aggressive or unique therapeutic approaches. PMID: 32929406 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32929406?dopt=Abstract

Source: Clinical Prostate Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Watson AP, Shabaneh A, Wang J, Dehm SM, Rao A, Ryan CJ Tags: Am J Clin Exp Urol Source Type: research